Getein Biotech's low P/E ratio is due to declining earnings....

Getein Biotech's low P/E ratio is due to declining earnings. Unless conditions improve, the low P/E ratio and falling share price may persist. The market's expected 41% growth next year puts the company's recent earnings decline into perspective.